Regarding your Instant Poll (posted on your Web site in October) about whether triptans should go over the counter, they shouldn't. Side effects or overdose reactions are far too severe. But insurance companies should make them more accessible to patients by eliminating preauthorization or quantity control to legitimate patients who have been counseled by a doctor/pharmacist. I personally know some patients who have stopped trying to fill legitimate Rxs for triptans because of all the red tape involved and the length of time to actually get the drug.
Mental Health and CBD: What's the Latest Info
October 27th 2022Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda Professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.
Promoting Health Equity and Achieving Pharmacoequity to Ensure Medication Access for All
March 27th 2023Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.
2 Clarke Drive
Cranbury, NJ 08512